Bionexus Gene Lab CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Bionexus Gene Lab Corp. filed its annual report for the fiscal year ended December 31, 2025, detailing revenue decline, strategic partnerships, and ongoing governance remediation.
NASDAQ
BioNexus Gene Lab Corp. files an amendment to its 2024 annual report to include its policy on recovery of erroneously awarded compensation (clawback policy) to comply with SEC and Nasdaq regulations.
NASDAQ
BioNexus Gene Lab Corp. announces its fiscal year 2024 results, highlighting a strong liquidity position, strategic innovation initiatives, and proactive governance enhancements while addressing Nasdaq compliance challenges.
NASDAQ
BioNexus Gene Lab Corp. has filed an amendment to its annual report to address comments from the SEC regarding the effectiveness of its disclosure controls and procedures.
NASDAQ
Bionexus Gene Lab Corp. has filed an amendment to its 2022 annual report to correct inaccuracies regarding its internal controls and procedures, following a comment letter from the SEC.
NASDAQ
BioNexus Gene Lab Corp. reports a decrease in revenue and a net loss for 2023, alongside significant changes in management and strategic direction.